持续低水平病毒血症是抗逆转录病毒治疗中病毒学失败的独立危险因素
结果显示pLLV(HR 3.46,95%CI 2.42-4.93)和高水平病毒血症(HR 2.29,95%CI 1.78-2.96)均与VF独立相关,提示持续LLV与不良病毒学后果相关。
要点
- pLLV定义为至少25%的病毒载量检测值在50-199拷贝/mL。
- pLLV是病毒学失败的独立危险因素(HR 3.46,95%CI 2.42-4.93)。
- 高龄启动ART及使用INSTI或NNRTI与较低病毒学失败风险相关。
核心结论
- 持续低水平病毒血症(pLLV)是病毒学失败的独立危险因素,与不良病毒学后果相关。
主要发现
- 中位年龄29.2岁,93%男性,41%黑人;383例(19%)发生病毒学失败。
- 调整混杂因素后,pLLV与VF的HR为3.46(95%CI 2.42-4.93),hLV的HR为2.29(95%CI 1.78-2.96)。
- 黑人种族(HR 1.33,95%CI 1.06-1.68)和ART前使用抗逆转录病毒药物(HR 1.79,95%CI 1.34-2.38)与VF风险升高相关。
- 启动ART时年龄较大(HR 0.71,95%CI 0.61-0.82)、使用NNRTI(HR 0.68,95%CI 0.51-0.90)或INSTI(HR 0.26,95%CI 0.13-0.53)与VF风险降低相关。
关键数值与推荐
- 病毒学失败定义为确认的病毒载量≥200拷贝/mL或任何病毒载量>1000拷贝/mL。
- pLLV定义为至少25%的病毒载量检测值在50-199拷贝/mL。
- 间歇性LLV(iLLV)定义为病毒载量50-199拷贝/mL的检测值占比<25%。
- 高水平病毒血症(hLV)定义为病毒载量200-1000拷贝/mL。
临床怎么用
- 对于接受ART且出现持续低水平病毒血症(50-199拷贝/mL占≥25%)的患者,应警惕病毒学失败风险,加强病毒载量监测并考虑优化治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether persistent low-level viremia (pLLV) predicts virologic failure (VF) is unclear. We used data from the US Military HIV Natural History Study (NHS), to examine the association of pLLV and VF. METHODS: NHS subjects who initiated combination antiretroviral therapy (ART) after 1996 were included if they had 2 or more VLs measured with a lower limit of detection of ≤50 copies/mL. VF was defined as a confirmed VL ≥200 copies/mL or any VL >1000 copies/mL. Participants were categorized into mutually exclusive virologic categories: intermittent LLV (iLLV) (VL of 50-199 copies/mL on <25% of measurements), pLLV (VL of 50-199 copies/mL on ≥25% of measurements), high-level viremia (hLV) (VL of 200-1000 copies/mL), and continuous suppression (all VL <50 copies/mL). Cox proportional hazards models were used to evaluate the association between VF and LLV; hazard ratios and 95% confidence interval (CI) are presented. RESULTS: Two thousand six subjects (median age 29.2 years, 93% male, 41% black) were included; 383 subjects (19%) experienced VF. After adjusting for demographics, VL, CD4 counts, ART regimen, prior use of mono or dual antiretrovirals, and time to ART start, pLLV (3.46 [2.42-4.93]), and hLV (2.29 [1.78-2.96]) were associated with VF. Other factors associated with VF include black ethnicity (1.33 [1.06-1.68]) and antiretroviral use prior to ART (1.79 [1.34-2.38]). Older age at ART initiation (0.71 [0.61-0.82]) and non-nucleoside reverse transcriptase inhibitor (0.68 [0.51-0.90]) or integrase strand transfer inhibitor use (0.26 [0.13-0.53]) were protective. CONCLUSION: Our data add to the body of evidence that suggests persistent LLV is associated with deleterious virologic consequences.
引用
- Joya C, Won SH, Schofield C, et al. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure. Clin Infect Dis. 2019. PMID: 30785191. doi:10.1093/cid/ciz129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。